Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global cholera vaccines market stood at a value of around USD 80 million in 2020. The market is further expected to grow at a CAGR of 8.6% in the forecast period of 2022-2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on product, Dukoral is predicted to hold a significant share of the market. The increasing demand for the product can be attributed to the fact that Dukoral is the only oral (drinkable) vaccine available in the market, which provides protection against cholera and diarrhoea caused by Enterotoxigenic E. coli (ETEC), the most common cause of diarrhoea for travellers to many parts of the world. This factor is contributing to the growth of the segment.
Further, Dukoral can be given to adults and children 2 years of age and older. Apart from this, the growing population in the cholera endemic region as well as the individuals travelling to the said region are also anticipated to propel the segment growth in the coming years.
The Asia Pacific region is estimated to hold a substantial share of the global cholera vaccines market in the forecast period. This growth can be attributed to the increasing prevalence of cholera in the region. In addition, the increased government investments supporting the immunisation process are also anticipated to propel the market growth in the forecast period. Moreover, the growing awareness pertaining to the vaccines and the increased availability of oral vaccines in the region are also predicted to bolster the market growth in the coming years. The adoption of water, sanitation, and hygiene practices has proven to be effective in protecting the population, along with the use of oral cholera vaccines (OCVs).
Meanwhile, the demand for cholera vaccines in North America is also expected to witness a considerable growth over the forecast period owing to the increased government expenditure on immunisation programmes in the region. The increasing number of travellers in North American countries, including the United States and Canada, are significantly contributing to the rising vaccine demands. In June 2016, the Food and Drug Administration (FDA) approved Vaxchora (PaxVax, Inc.) for United States (US) travellers, as no cholera vaccine was available to help protect them until that time. Vaxchora™ (CVD 103-HgR), an oral live attenuated vaccine, is the first and only cholera vaccine available in the United States.
Cholera refers to an acute diarrhoeal illness, which is caused by an infection in the intestine. It is spread through the ingestion of water or food that is contaminated with the bacterium Vibrio cholerae. An estimated number 1.3 to 4.0 million cases of cholera are reported every year, with 21,000 to 1,43,000 deaths worldwide due to cholera. The cholera vaccines are essential in controlling the spread of cholera, which is recommended by the WHO for individuals travelling to cholera affected regions, as well as people residing in such areas.
By product, the cholera vaccines market is divided into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
According to the WHO statistics, an estimated 1.3 to 4.0 million cases of cholera are reported every year. The disease impacts children as well as adults and can result in death, if left untreated. Cholera is linked to the decreased availability of clean water and sanitation facilities. In this regard, the WHO Global Task Force on Cholera Control (GTFCC), a programme aimed at controlling the spread of cholera by 2030, was launched to reduce the mortality risk associated with the disease by 90% in cholera prone areas such as Asia and Africa. This is leading to the increased demand for cholera vaccines around the globe. In addition, rising investments by the governments to develop efficient vaccines to treat cholera are expected to further propel the cholera vaccines market forward. As cholera is a public health threat, the governments are making significant investments to provide improved water and sanitation facilities to the least privileged population, that remains largely affected by the disease due to poor sanitation. Moreover, the increasing concerns associated with cholera outbreaks and the emergence of new strains that might be of greater severity are leading to a rise in research and development activities by both government and private bodies. These factors are anticipated to positively impact the market growth in the forecast period.
The report gives a detailed analysis of the following key players in the global cholera vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model and SWOT analysis.
|Scope of the Report||Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Region|
|Breakup by Product||Dukoral, Shanchol, Vaxchora, Others|
|Breakup by Region||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
|Market Dynamics||SWOT, Porter's Five Forces, Key Indicators for Price and Demand|
|Competitive Landscape||Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications|
|Companies Covered||Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Intervet Inc., EuBiologics Co., Ltd., Others|
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
7 Industry Opportunities and Challenges
8 Global Cholera Vaccines Market Analysis
8.1 Key Industry Highlights
8.2 Global Cholera Vaccines Historical Market (2017-2021)
8.3 Global Cholera Vaccines Market Forecast (2022-2027)
8.4 Global Cholera Vaccines Market by Product
220.127.116.11 Market Share
18.104.22.168 Historical Trend (2017-2021)
22.214.171.124 Forecast Trend (2022-2027)
126.96.36.199 Market Share
188.8.131.52 Historical Trend (2017-2021)
184.108.40.206 Forecast Trend (2022-2027)
220.127.116.11 Market Share
18.104.22.168 Historical Trend (2017-2021)
22.214.171.124 Forecast Trend (2022-2027)
8.5 Global Cholera Vaccines Market by Region
8.5.1 Market Share
126.96.36.199 North America
188.8.131.52 Asia Pacific
184.108.40.206 Latin America
220.127.116.11 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
18.104.22.168 United States of America
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
22.214.171.124 United Kingdom
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
126.96.36.199 Saudi Arabia
188.8.131.52 United Arab Emirates
184.108.40.206 South Africa
10 Market Dynamics
10.1 SWOT Analysis
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Sanofi-aventis Groupe
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
12.2.2 Emergent BioSolutions Inc.
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
12.2.3 Valneva SE
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
12.2.4 GlaxoSmithKline plc.
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
12.2.5 Intervet Inc.
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
12.2.6 EuBiologics Co., Ltd.
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Cholera Vaccines Market: Key Industry Highlights, 2016 and 2026
2. Global Cholera Vaccines Historical Market: Breakup by Product (USD Million), 2017-2021
3. Global Cholera Vaccines Market Forecast: Breakup by Product (USD Million), 2022-2027
4. Global Cholera Vaccines Historical Market: Breakup by Region (USD Million), 2017-2021
5. Global Cholera Vaccines Market Forecast: Breakup by Region (USD Million), 2022-2027
6. North America Cholera Vaccines Historical Market: Breakup by Country (USD Million), 2017-2021
7. North America Cholera Vaccines Market Forecast: Breakup by Country (USD Million), 2022-2027
8. Europe Cholera Vaccines Historical Market: Breakup by Country (USD Million), 2017-2021
9. Europe Cholera Vaccines Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Asia Pacific Cholera Vaccines Historical Market: Breakup by Country (USD Million), 2017-2021
11. Asia Pacific Cholera Vaccines Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Latin America Cholera Vaccines Historical Market: Breakup by Country (USD Million), 2017-2021
13. Latin America Cholera Vaccines Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Middle East and Africa Cholera Vaccines Historical Market: Breakup by Country (USD Million), 2017-2021
15. Middle East and Africa Cholera Vaccines Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Global Cholera Vaccines Market Structure
In 2020, the global cholera vaccines market attained a value of nearly USD 80 million.
The market is projected to grow at a CAGR of 8.6% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach a value of USD 129.4 million by 2026.
The major drivers of the industry, such as the increased demand for cholera vaccines in the cholera endemic region, growing pharmaceutical industry, rising demand for cholera vaccines for travellers, and the rising incidences of cholera, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the rising investments in research and development of vaccines by the leading life sciences companies.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant products considered in the market report include Dukoral, Shanchol, Vaxchora, and others.
The major players in the industry are Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Intervet Inc., EuBiologics Co., Ltd., and others.
The global cholera vaccines market attained a value of USD 80 million in 2020, driven by the rising incidences of cholera worldwide. Aided by the growing investments in the pharmaceutical industry, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 8.6%. The market is projected to reach USD 129.4 million by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. On the basis of product, the industry can be segmented into Dukoral, Shanchol, Vaxchora, and others. The major regional markets for cholera vaccines are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Intervet Inc., and EuBiologics Co., Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.